NCT01785472View on ClinicalTrials.gov

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

1,438

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Essential Hypertension
Interventions
DRUG

LCZ696

LCZ696 200 mg tablet

DRUG

Olmesartan

Olmesartan 20 mg capsule

DRUG

Placebo of LCZ696

Placebo tablet of LCZ696 200 mg once daily

DRUG

Placebo of Olmesartan

Placebo capsule of olmesartan 20 mg once daily

Trial Locations (50)

110

Novartis Investigative Site, Taipei

640

Novartis Investigative Site, Douliu

807

Novartis Investigative Site, Kaohsiung City

1100

Novartis Investigative Site, Quezon City

1102

Novartis Investigative Site, Quezon City

10002

Novartis Investigative Site, Taipei

10400

Novartis Investigative Site, Rajathevee

10700

Novartis Investigative Site, Bangkok

22060

Novartis Investigative Site, Taipei County

23561

Novartis Investigative Site, New Taipei City

40002

Novartis Investigative Site, Khon Kaen

40447

Novartis Investigative Site, Taichung

50200

Novartis Investigative Site, Chiang Mai

70403

Novartis Investigative Site, Tainan City

82445

Novartis Investigative Site, Kaohsiung City

100020

Novartis Investigative Site, Beijing

100029

Novartis Investigative Site, Beijing

100034

Novartis Investigative Site, Beijing

100044

Novartis Investigative Site, Beijing

110016

Novartis Investigative Site, Shenyang

150001

Novartis Investigative Site, Harbin

169609

Novartis Investigative Site, Singapore

200025

Novartis Investigative Site, Shanghai

200031

Novartis Investigative Site, Shanghai

200032

Novartis Investigative Site, Shanghai

200072

Novartis Investigative Site, Shanghai

200120

Novartis Investigative Site, Shanghai

210009

Novartis Investigative Site, Nanjing

215006

Novartis Investigative Site, Suzhou

300121

Novartis Investigative Site, Tianjin

300142

Novartis Investigative Site, Tianjin

310013

Novartis Investigative Site, Hangzhou

330006

Novartis Investigative Site, Nanchang

350001

Novartis Investigative Site, Fuzhou

400010

Novartis Investigative Site, Chongqing

400042

Novartis Investigative Site, Chongqing

410003

Novartis Investigative Site, Changsha

430030

Novartis Investigative Site, Wuhan

510080

Novartis Investigative Site, Guangzhou

530021

Novartis Investigative Site, Nanning

710004

Novartis Investigative Site, Xi’an

710061

Novartis Investigative Site, Xi’an

Unknown

Novartis Investigative Site, Fuzhou

Novartis Investigative Site, Hong Kong

050000

Novartis Investigative Site, Shijiazhuang

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

06591

Novartis Investigative Site, Seoul

08308

Novartis Investigative Site, Seoul

410-719

Novartis Investigative Site, Koyang

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY